JPWO2023079485A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2023079485A5
JPWO2023079485A5 JP2024525880A JP2024525880A JPWO2023079485A5 JP WO2023079485 A5 JPWO2023079485 A5 JP WO2023079485A5 JP 2024525880 A JP2024525880 A JP 2024525880A JP 2024525880 A JP2024525880 A JP 2024525880A JP WO2023079485 A5 JPWO2023079485 A5 JP WO2023079485A5
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
acid sequence
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540226A5 (https=
JP2024540226A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/060604 external-priority patent/WO2023079485A1/en
Publication of JP2024540226A publication Critical patent/JP2024540226A/ja
Publication of JP2024540226A5 publication Critical patent/JP2024540226A5/ja
Publication of JPWO2023079485A5 publication Critical patent/JPWO2023079485A5/ja
Pending legal-status Critical Current

Links

JP2024525880A 2021-11-03 2022-11-03 抗タウ抗体組成物、投薬形態、及び方法 Pending JP2024540226A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163275045P 2021-11-03 2021-11-03
US63/275,045 2021-11-03
US202163290278P 2021-12-16 2021-12-16
US63/290,278 2021-12-16
US202263316582P 2022-03-04 2022-03-04
US202263316616P 2022-03-04 2022-03-04
US63/316,616 2022-03-04
US63/316,582 2022-03-04
PCT/IB2022/060604 WO2023079485A1 (en) 2021-11-03 2022-11-03 Anti-tau antibody compositions, dosage forms, and methods

Publications (3)

Publication Number Publication Date
JP2024540226A JP2024540226A (ja) 2024-10-31
JP2024540226A5 JP2024540226A5 (https=) 2025-12-01
JPWO2023079485A5 true JPWO2023079485A5 (https=) 2025-12-01

Family

ID=84360026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525880A Pending JP2024540226A (ja) 2021-11-03 2022-11-03 抗タウ抗体組成物、投薬形態、及び方法

Country Status (8)

Country Link
EP (1) EP4426336A1 (https=)
JP (1) JP2024540226A (https=)
KR (1) KR20240118915A (https=)
AU (1) AU2022381556A1 (https=)
CA (1) CA3237660A1 (https=)
MX (1) MX2024005430A (https=)
TW (1) TW202334201A (https=)
WO (1) WO2023079485A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
CN117946264B (zh) * 2024-03-21 2024-06-04 江西赛基生物技术有限公司 一种抗Tau蛋白单克隆抗体及其应用
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3074420A2 (en) * 2013-11-27 2016-10-05 Ipierian, Inc. Methods of treating a tauopathy
MA48595A (fr) * 2016-12-07 2020-03-18 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
EP3697814A1 (en) 2017-10-16 2020-08-26 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20240101654A1 (en) * 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies

Similar Documents

Publication Publication Date Title
CN104105708B (zh) PDGF受体β结合多肽
JP2013542194A5 (https=)
JP2020037555A5 (https=)
JP2020528768A5 (https=)
JP2025131696A5 (https=)
JP2015514110A5 (https=)
JP2018535650A5 (https=)
RU2013155906A (ru) Антитела анти-angptl3 и их применение
JP2025183307A5 (https=)
FI3740504T3 (fi) CD70-yhdistelmähoito
JP2016538876A5 (https=)
JP2021532126A5 (https=)
JP2023055904A5 (https=)
JP6949012B2 (ja) B型肝炎表面抗原に対する抗体及びその使用
JP2018522540A5 (https=)
RU2016122340A (ru) Il-17a-связующий агент и способы его применения
JP2020522280A5 (https=)
JP2021529766A5 (https=)
JP2019509714A5 (https=)
JP2021533142A5 (https=)
JPWO2020128049A5 (https=)
JPWO2023079485A5 (https=)
JPWO2020023530A5 (https=)
JPWO2020257289A5 (https=)
JPWO2023019171A5 (https=)